BioNTech says possible to adapt vaccine for Omicron quickly
Germany’s BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the emergence of the Omicron variant.
The new coronavirus variant might be able to infect vaccinated people and will most likely be able to infect people with high exposure. It is not clear whether this variant produces more severe disease.
Mutations in the virus meant it was more likely that annual vaccinations would become likely, as is the case with seasonal flu and that a new vaccine would be needed against COVID-19, although it was not yet clear when it would be required.